Sec Form 4 Filing - Sanderling Venture Partners VI LP @ CalciMedica, Inc. - 2024-01-23

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Sanderling Venture Partners VI LP 2. Issuer Name and Ticker or Trading Symbol CalciMedica, Inc. [ CALC] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 1300 S. EL CAMINO REAL SUITE 203, 3. Date of Earliest Transaction (MM/DD/YY) 01/23/2024 (Street) SAN MATEO, CA94402 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 01/23/2024 P( 1 ) 243,356 A $ 3.702 946,744 D Common Stock 01/23/2024 P( 1 ) 144,676 A $ 3.702 727,433 I By Sanderling Venture Partners VI Co-Investment Fund, L.P. Common Stock 01/23/2024 P( 1 ) 194,472 A $ 3.702 435,148 I By Sanderling Ventures VII, L.P. Common Stock 01/23/2024 P( 1 ) 51,032 A $ 3.702 114,260 I By Sanderling Ventures VII (Canada), L.P. Common Stock 01/23/2024 P( 1 ) 13,184 A $ 3.702 27,609 I By Sanderling Ventures VII Annex Fund, L.P. Common Stock 01/23/2024 P( 1 ) 3,920 A $ 3.702 21,602 I By Sanderling Ventures Management VI Common Stock 01/23/2024 P( 1 ) 28,744 A $ 3.702 30,292 I By Sanderling Ventures Management VII

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Warrant $ 5.36 01/23/2024 P( 1 ) 121,678 01/23/2024( 2 ) 12/31/2024( 2 ) Common Stock 121,678 $ 0.125 121,678 D Warrant $ 7.15 01/23/2024 P( 1 ) 121,678 01/23/2024( 3 ) 12/31/2026( 3 ) Common Stock 121,678 $ 0.125 121,678 D Warrant $ 5.36 01/23/2024 P( 1 ) 72,338 01/23/2024( 2 ) 12/31/2024( 2 ) Common Stock 72,338 $ 0.125 72,338 I By Sanderling Venture Partners VI Co-Investment Fund, L.P. Warrant $ 7.15 01/23/2024 P( 1 ) 72,338 01/23/2024( 3 ) 12/31/2026( 3 ) Common Stock 72,338 $ 0.125 72,338 I By Sanderling Venture Partners VI Co-Investment Fund, L.P. Warrant $ 5.36 01/23/2024 P( 1 ) 97,236 01/23/2024( 2 ) 12/31/2024( 2 ) Common Stock 97,236 $ 0.125 97,236 I By Sanderling Ventures VII, L.P. Warrant $ 7.15 01/23/2024 P( 1 ) 97,236 01/23/2024( 3 ) 12/31/2026( 3 ) Common Stock 97,236 $ 0.125 97,236 I By Sanderling Ventures VII, L.P. Warrant $ 5.36 01/23/2024 P( 1 ) 25,516 01/23/2024( 2 ) 12/31/2024( 2 ) Common Stock 25,516 $ 0.125 25,516 I By Sanderling Ventures VII (Canada), L.P. Warrant $ 7.15 01/23/2024 P( 1 ) 25,516 01/23/2024( 3 ) 12/31/2026( 3 ) Common Stock 25,516 $ 0.125 25,516 I By Sanderling Ventures VII (Canada), L.P. Warrant $ 5.36 01/23/2024 P( 1 ) 6,592 01/23/2024( 2 ) 12/31/2024( 2 ) Common Stock 6,592 $ 0.125 6,592 I By Sanderling Ventures VII Annex Fund, L.P. Warrant $ 7.15 01/23/2024 P( 1 ) 6,592 01/23/2024( 3 ) 12/31/2026( 3 ) Common Stock 6,592 $ 0.125 6,592 I By Sanderling Ventures VII Annex Fund, L.P. Warrant $ 5.36 01/23/2024 P( 1 ) 1,960 01/23/2024( 2 ) 12/31/2024( 2 ) Common Stock 1,960 $ 0.125 1,960 I By Sanderling Ventures Management VI Warrant $ 7.15 01/23/2024 P( 1 ) 1,960 01/23/2024( 3 ) 12/31/2026( 3 ) Common Stock 1,960 $ 0.125 1,960 I By Sanderling Ventures Management VI Warrant $ 5.36 01/23/2024 P( 1 ) 14,372 01/23/2024( 2 ) 12/31/2024( 2 ) Common Stock 14,372 $ 0.125 14,372 I By Sanderling Ventures Management VII Warrant $ 7.15 01/23/2024 P( 1 ) 14,372 01/23/2024( 3 ) 12/31/2026( 3 ) Common Stock 14,372 $ 0.125 14,372 I By Sanderling Ventures Management VII

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Sanderling Venture Partners VI LP 1300 S. EL CAMINO REAL SUITE 203 SAN MATEO, CA94402 X Sanderling Venture Partners VI Co Investment Fund LP 1300 S EL CAMINO REAL SUITE 203 SAN MATEO, CA94402 X Sanderling Ventures Management VI 1300 S EL CAMINO REAL SUITE 203 SAN MATEO, CA94402 X Sanderling Ventures VII, L.P. 1300 S. EL CAMINO REAL SUITE 203 SAN MATEO, CA94402 X Sanderling Ventures VII Annex Fund, L.P. 1300 S EL CAMINO REAL SUITE 203 SAN MATEO, CA94402 X Sanderling Ventures VII (Canada), L.P. 1300 S. EL CAMINO REAL SUITE 203 SAN MATEO, CA94402 X Sanderling Ventures Management VII 1300 S. EL CAMINO REAL SUITE 203 SAN MATEO, CA94402 X Signatures /s/ Sanderling Venture Partners VI, L.P., By: /s/ Timothy C. Mills, Managing Director of Middleton, McNeil & Mills Associates VI, L.P., its General Partner 01/25/2024 Signature of Reporting Person Date /s/ Sanderling Venture Partners VI Co-Investment Fund, L.P., By: /s/ Timothy C. Mills, Managing Director of Middleton, McNeil & Mills Associates VI, LLC, its General Partner 01/25/2024 Signature of Reporting Person Date /s/ Sanderling Ventures VII (Canada), L.P., By: /s/ D. Michael Dixon, President of Sanderling Ventures VII (Canada) GP Inc., General Partner of Sanderling Ventures VII (Canada) G.P., L.P, its General Partner 01/25/2024 Signature of Repor ting Person Date /s/ Sanderling Ventures VII, L.P. , By: /s/ Timothy C. Mills, Managing Director of M4 Partners VII, LLC, its General Partner 01/25/2024 Signature of Reporting Person Date /s/ Sanderling Ventures VII Annex Fund, L.P., By: /s/ Timothy C. Mills, Managing Director of M4 Partners VII Annex, LLC, its General Partner 01/25/2024 Signature of Reporting Person Date /s/ Sanderling Ventures Management VII, By: /s/ Timothy C. Mills, Owner 01/25/2024 Signature of Reporting Person Date /s/ Sanderling Ventures Management VI, By: /s/ Timothy C. Mills, Owner 01/25/2024 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. ( 2 )The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. ( 3 )The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.